Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Urologie
Erschienen in: Der Urologe 9/2005

01.09.2005 | Leitthema

PSA-Rezidiv nach primär kurativer Therapie — lokal oder systemisch?

Wann ist eine kurative Zweittherapie noch möglich?

verfasst von: M. P. Wirth, Dr. F. M. Engelhardt

Erschienen in: Die Urologie | Ausgabe 9/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine alleinige PSA-Erhöhung als erster Hinweis auf ein Rezidiv oder eine Progression eines Prostatakarzinoms nach primär kurativem Therapieansatz stellt ein häufiges diagnostisches und therapeutisches Problem dar. Da ein weiterer kurativer Therapieversuch nur bei einem Lokalrezidiv sinnvoll ist, sollte zuvor eine Metastasierung weitestgehend ausgeschlossen werden. Die bildgebenden Verfahren können bisher keine ausreichende Sicherheit für den Nachweis eines frühen Lokalrezidivs wie auch für den Ausschluss einer Metastasierung bieten. Deshalb ist es sinnvoll, sich primär an der PSA-Kinetik sowie bestimmten pathologischen Parametern zu orientieren. Der histologische Nachweis eines Lokalrezidivs nach radikaler Prostatektomie vor einer Salvagetherapie ist nicht notwendig. Im Falle eines Rezidivs nach Strahlentherapie ist jedoch eine histologische Sicherung sinnvoll. Die Wahl der Salvagetherapie hängt von dem primären kurativen Therapieansatz und der Lebenserwartung des Patienten ab.
Literatur
1.
American Society for Therapeutic Radiology and Oncology (1997) Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37: 1035–1041CrossRefPubMed
2.
Albertsen PC, Hanley JA, Penson DF, Fine J (2004) Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171: 2221–2225CrossRefPubMed
3.
Anscher MS, Clough R, Dodge R (2000) Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48: 369–375CrossRefPubMed
4.
Anscher MS (2004) Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA 291: 1380–1382CrossRefPubMed
5.
Bahn DK, Ventura CA, Lee F, Silverman JM, Bahn E (2003) Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a 7-year follow-up (abstract). J Urol 169: DP 15
6.
Beyer DC (1999) Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 54: 880–883CrossRefPubMed
7.
Burton S, Brown DM, Colonias A et al. (2000) Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation. Urology 56: 833–838CrossRefPubMed
8.
Cher ML, Bianco FJ Jr, Lam JS et al. (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160: 1387–1391CrossRefPubMed
9.
Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB (2001) Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 165: 1937–1941; discussion 1941–1942CrossRefPubMed
10.
Connolly JA, Shinohara K, Presti JC Jr, Carroll PR (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47: 225–231CrossRefPubMed
11.
Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF (1999) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17: 1155PubMed
12.
Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA (2000) Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163: 1085–1089CrossRefPubMed
13.
D’Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567–4573CrossRefPubMed
14.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376–1383PubMed
15.
D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH (2004) Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172: S42–S46; discussion S46–S47PubMed
16.
D’Amico AV, Moul JW, Carroll PR et al. (2004) Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 96: 509–515PubMed
17.
de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44: 32–38; discussion 38–39CrossRefPubMed
18.
De La Taille A, Benson MC, Bagiella E et al. (2000) Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int 85: 281–286CrossRefPubMed
19.
DeGrado TR, Coleman RE, Wang S et al. (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61: 110–117PubMed
20.
Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V (2003) PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol 43: 12–27CrossRefPubMed
21.
Evans CP (2002) Follow-up surveillance strategies for genitourinary malignancies. Cancer 94: 2892–2905CrossRefPubMed
22.
Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P (1993) The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 149: 1024–1028PubMed
23.
Garg MK, Tekyi-Mensah S, Bolton S et al. (1998) Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 51: 998–1002CrossRefPubMed
24.
Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM (2001) Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 40: 124–129CrossRefPubMed
25.
Gelet A, Chapelon JY, Poissonnier L et al. (2004) Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63: 625–629CrossRefPubMed
26.
Ghafar MA, Johnson CW, De La Taille A et al. (2001) Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 166: 1333–1337; discussion 1337–1338CrossRefPubMed
27.
Gheiler EL, Tefilli MV, Tiguert R et al. (1998) Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51: 789–795CrossRefPubMed
28.
Gomez P, Manoharan M, Kim SS, Soloway MS (2004) Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 94: 299–302CrossRefPubMed
29.
Gottfried HW, Bartsch G Jr, Messer P, Hautmann RE, Reske SN, Blumstein NM (2004) Das 11C-Cholin-PET/CT, ein neues bildgebendes Verfahren in der Prostatakarzinom-Diagnostik. Urologe 43 [Suppl 1]: 57
30.
Grado GL, Collins JM, Kriegshauser JS et al. (1999) Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53: 2–10CrossRefPubMed
31.
Gretzer MB, Trock BJ, Han M, Walsh PC (2002) A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 168: 1419–1422CrossRefPubMed
32.
Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36: 31–35CrossRef
33.
Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A (1998) Positron emission tomography in urological oncology. J Urol 159: 347–356PubMed
34.
Hricak H, Schoder H, Pucar D et al. (2003) Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 30: 616–634PubMed
35.
Huch Boni RA, Meyenberger C, Pok Lundquist J, Trinkler F, Lutolf U, Krestin GP (1996) Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies. Abdom Imaging 21: 345–352CrossRefPubMed
36.
Jhaveri FM, Zippe CD, Klein EA, Kupelian PA (1999) Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 54: 884–890CrossRefPubMed
37.
Kahn D, Williams RD, Manyak MJ et al. (1998) 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159: 2041–2046; discussion 2046–2047CrossRefPubMed
38.
Kane CJ, Amling CL, Johnstone PA et al. (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61: 607–611CrossRefPubMed
39.
Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR (1999) The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol 162: 427–432CrossRefPubMed
40.
Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR (2001) Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 166: 111–115CrossRefPubMed
41.
Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN (2002) Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29: 1380–1384 (Epub 2002 Jul 27)CrossRefPubMed
42.
Kramer S, Gorich J, Gottfried HW et al. (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70: 995–999PubMed
43.
Lattouf JB, Saad F (2003) Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? Eur Urol 43: 333–336CrossRefPubMed
44.
Laufer M, Pound CR, Carducci MA, Eisenberger MA (2000) Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 55: 309–315CrossRefPubMed
45.
Lee WR, Hanks GE, Hanlon A (1997) Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 15: 230–238PubMed
46.
Leibovich BC, Zincke H, Blute ML et al. (2001) Recurrent prostate cancer after radiation Therapy: salvage prostatectomy versus salvage cryosurgery. J Urol 165: 1595
47.
Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM (2001) Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19: 1030–1039PubMed
48.
Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219: 432–439PubMed
49.
Lightner DJ, Lange PH, Reddy PK, Moore L (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144: 921–926PubMed
50.
Linne C, Strumpf A, Hakenberg OW, Mäding P, Wirth MP (2004) Positronenemissionstomographie mit 11-C-Acetat bei der Diagnostik des PSA-Rezidivs. Urologe 43 [Suppl 1]: 57
51.
McDonough MJ, Feldmeier JJ, Parsai I, Dobelbower RR Jr, Selman SH (2001) Salvage external beam radiotherapy for clinical failure after cryosurgery for prostate cancer. Int J Radiat Oncol Biol Phys 51: 624–627CrossRefPubMed
52.
Moul JW, Wu H, Sun L et al. (2004) Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171: 1141–1147CrossRefPubMed
53.
Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd, Carroll PR (1999) Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 54: 1049–1057CrossRefPubMed
54.
Obek C, Neulander E, Sadek S, Soloway MS (1999) Is there a role for digital rectal examination in the followup of patients after radical prostatectomy? J Urol 162: 762–764CrossRefPubMed
55.
Ornstein DK, Oh J, Herschman JD, Andriole GL (1998) Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 25: 591–601CrossRefPubMed
56.
Oyama N, Miller TR, Dehdashti F, Siegel BA et al. (2003) 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44: 549–555PubMed
57.
Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC (1993) Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713–725PubMed
58.
Partin AW, Pearson JD, Landis PK et al. (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649–659CrossRefPubMed
59.
Partin AW, Eisenberger MA, Sinibaldi VJ, Humphreys E, Mangold LA, Walsh PC (2004) Prostate specific antigen doubling time (PSADT) predicts for distant failure and prostate cancer specific survival (PCSS) in men with biocgemical relapse after radical prostatectomy (RP). J Clin Oncol 22: 4555
60.
Patel A, Dorey F, Franklin J, deKernion JB (1997) Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158: 1441–1445CrossRefPubMed
61.
Picchio M, Messa C, Landoni C et al. (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169: 1337–1340CrossRefPubMed
62.
Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC (1999) Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 162: 1337–1340CrossRefPubMed
63.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597CrossRefPubMed
64.
Raj GV, Partin AW, Polascik TJ (2002) Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94: 987–996CrossRefPubMed
65.
Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76: 576–581PubMed
66.
Rosser CJ, Kuban DA, Levy LB et al. (2002) Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 168: 2001–2005CrossRefPubMed
67.
Salomon L, Anastasiadis AG, Antiphon P et al. (2003) Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol Int 70: 291–296CrossRefPubMed
68.
Sanz G, Robles JE, Gimenez M et al. (1999) Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84: 1028–1031CrossRefPubMed
69.
Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM (1997) Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38: 941–947CrossRefPubMed
70.
Scattoni V, Roscigno M, Raber M et al. (2003) Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44: 407–414CrossRefPubMed
71.
Seitz M, Zaak D, Scher B, Staehler M, Schneede P (2004) Diagnostischer Nutzen der 11C-Cholin-Positronenemissionstomographie/Computertomographie (PET/CT) beim PSA-Progress nach Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom. Urologe 43 [Suppl 1]: 72
72.
Sella T, Schwartz LH, Swindle PW et al. (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231: 379–385PubMed
73.
Seltzer MA, Barbaric Z, Belldegrun A et al. (1999) Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162: 1322–1328CrossRefPubMed
74.
Silverman JM, Krebs TL (1997) MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 168: 379–385PubMed
75.
Stephenson AJ, Scardino PT, Bianco FJ Jr, Diblasio CJ, Fearn PA, Eastham JA (2004) Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 172: 2239–2243CrossRefPubMed
76.
Stephenson AJ, Shariat SF, Zelefsky MJ et al. (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291: 1325–1332CrossRefPubMed
77.
Stock RG, Stone NN, Cesaretti JA (2003) Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 56: 448–453CrossRefPubMed
78.
Thuroff S, Chaussy C, Vallancien G et al. (2003) High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 17: 673–677CrossRefPubMed
79.
Touma NJ, Izawa JI, Chin JL (2005) Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 173: 373–379CrossRefPubMed
Metadaten
Titel
PSA-Rezidiv nach primär kurativer Therapie — lokal oder systemisch?
Wann ist eine kurative Zweittherapie noch möglich?
verfasst von
M. P. Wirth
Dr. F. M. Engelhardt
Publikationsdatum
01.09.2005
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 9/2005
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-005-0879-4

Weitere Artikel der Ausgabe 9/2005

Der Urologe 9/2005 Zur Ausgabe

URO-Telegramm

URO-Telegramm

Originalien

Erektile Dysfunktion bei Männern in der zweiten Lebenshälfte

Einführung zum Thema

Urologische Tumornachsorge — warum und wie?

Berufspolitik BDU

Berufspolitik BDU

Geschichte der Urologie

Der „Pisse-Prophet“ oder „der englische Wahrsager aus dem Urin“

Kasuistiken

Das Schwannom der Niere

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise